WHO Updates
The latest guidances, approvals, and safety alerts from WHO, curated by automated regulatory intelligence.
Webinar invitation focusing on how to manage reportable changes, implying expectations for structured change assessment and timely regulatory communication.
WHO has added two STANDARD Q malaria rapid diagnostic tests to its list of prequalified in vitro diagnostic (IVD) products, enabling greater access and…
Establishes a WHO public consultation process (until 30 October 2026) for a new Quality Assurance Mechanism pilot covering independent WHO assessment of…
Schedules WHO prequalification In Vitro Diagnostics Assessment Sessions across multiple 2027 date windows, enabling applicants to plan submission and…
Lists the RADIONE Ebola Detection Kit under WHO’s Emergency Use Listing (EUL), increasing the availability of quality-assured Ebola molecular diagnostics for…
Adds the BioFire® Global Fever Special Pathogens Panel to WHO’s Emergency Use Listing (EUL), expanding availability of a quality-assured multiplex diagnostic…
WHO prequalifies the dolutegravir (sodium) active pharmaceutical ingredient (API) manufactured by Micro Labs Limited, enabling finished pharmaceutical product…
Launches a 44th WHO Prequalification Programme invitation requesting expressions of interest (EOIs) from API manufacturers to support WHO evaluation and…
Acknowledges WHO prequalification lists for UNFPA-prequalified male latex condoms and TCu380A IUDs, signaling the transition of related prequalification…
Launches eCTD submission capability for WHO PQT via the ePQS Portal, enabling more standardized electronic regulatory dossiers and potentially smoother…
Convenes a hybrid (in-person/virtual) 2026 global meeting for manufacturers and suppliers of health products to exchange experience, discuss emerging…
WHO prequalifies tenofovir disoproxil fumarate manufactured by Viyash Scientific Limited under the WHO API prequalification procedure.
Recognizes and operationalizes the ICH M7 (R2) less-than-lifetime (LTL) approach for nitrosamine impurity acceptable intakes for eligible short treatment…
Expands WHO Prequalification Unit product-evaluation engagement by updating the manufacturer invitation/EOI process and adding Acoziborole 320 mg tablets for…
Adds insulin glargine biosimilar BT-DM007 to the WHO prequalified list, marking the first such biosimilar approved through the abridged WHO prequalification…
Adds Macleods’s primaquine pediatric tablet strengths (2.5 mg, 5 mg, 7.5 mg) for Plasmodium vivax and Plasmodium ovale relapse prevention to the WHO…
Invites manufacturers of listed reproductive health medicines to submit an Expression of Interest (EOI) to the WHO Prequalification Unit for product…
Adds two new WHO Prequalification (PQT) entries to the prequalified list: Cipla’s nirmatrelvir/ritonavir co-blistered tablets for higher-risk non-severe…
Requests for Quotations (RFQs) have been extended to 10 October 2026 to recruit European Notified Bodies to expand WHO’s capacity for technical documentation…
Announces availability of the WHO PQT/AMD newsletter issue covering recent updates and activities related to the AMD program area.